Brian D. Gibson

Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.

Kaleo, Inc. develops drug/device combination products. Its products empower patients to gain freedom from their medical condition. The firm's capabilities include drug development, device development, regulatory and clinical, manufacturing, commercialization and data generation. The company was founded by Eric S. Edwards and Evan T. Edwards in 2005 and is headquartered in Richmond, VA.

Prescient Medical, Inc. develops diagnostic and therapeutic catheter-based devices for cardiologists. The company was founded by Janet Morrisin, David P. Hochman, Robert A. Lodder and Marvin L. Woodall in 2004 and is headquartered in Doylestown, PA.

Viveve, Inc. engages in the development of medical devices that promote personal health and wellness. It offers InControl products and Viveve system solutions. The company was founded by Jonathan B. Parmer in 2005 and is headquartered in Englewood, CO.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Part of MKS Instruments, Inc., Applied Intelligent Systems, Inc. is a company that manufactures machine vision computers. The company is based in Ann Arbor, MI. Applied Intelligent Systems was acquired by Electro Scientific Industries, Inc., part of MKS Instruments, Inc. from February 01, 2019 on December 02, 1997 for $60.55 million.

Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL.

Founded in 1998 by Roger Newton and Timothy Mayleben, Esperance BioVentures LLC is a venture capital firm located in Ann Arbor, Michigan

Michigan Ross Zell Lurie Institute / Venture Capital/ (Zell Lurie Institute) is a venture capital subsidiary of Zell Lurie Institute for Entrepreneurial Studies Studies founded in 1997 by Samuel Zell, Ann Lurie and Robert H. Lurie. The firm is headquartered in Ann Arbor, Michigan.

Wolverine Venture Fund, an evergreen fund invests in companies located in the US. The fund targets companies that are affiliated with the University of Michigan and operating in the fields of biomedicine, healthcare IT, advanced materials, and other emerging technologies. It provides financing for seed and early-stage capital requirements with an investment size ranging from $50,000 to $100,000 and also makes co-investment rights.

Biotronics, Inc. develops products and services for ultrasound evaluation of body composition and quality of beef cattle and swine. The firm’s services include swine and beef. It also offers image capture and analysis software and equipment products. The company was founded by Doyle E. Wilson and Viren Amin in 1998 and is headquartered in Ames, IA.

Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA.

Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.

A-Alpha Bio, Inc. designs and develops a drug discovery platform. The firm offers AlphaSeq platform. The company was founded by Randolph Lopez and David Younger in 2017 and is headquartered in Seattle, WA.

Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA.

Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102.

Illumisonics, Inc. develops and patents advanced optical imaging systems for pre-clinical and clinical applications. The company was founded in 2014 and is based in Waterloo, Canada, where it has offices and R&D facilities. Illumisonics' executive team has a track record of successfully building companies and improving outcomes for clinicians and patients. The Canadian company's technical R & D teams are pioneers in pars technology, which captures all light-matter interactions to yield unprecedented cellular and molecular information. Illumisonics works with market-leading partners to develop systems for specific applications. The company's goal is to enable medical personnel to drive better healthcare outcomes for patients while enhancing decision-making and reducing costs. The company was founded by Parsin Haji Reza, and the CEO is Scott C. Durbin.